• Milestone Payments Triggered following EC Approval

News & Views

Milestone Payments Triggered following EC Approval

Jun 15 2021

UK pharmaceutical company Diurnal Group specialising in chronic endocrine (hormonal) diseases, has announced a payment of $1.0 million of a possible $1.25 from its China partner Citrine Medicine, following the recent European Commission’s (EC) approval for Efmody® (hydrocortisone modified-release hard capsules) and the attainment by Citrine of certain development milestones in China for Alkindi® (hydrocortisone granules in capsules for opening). This followed the company’s extension of its exclusive license agreement with Citrine covering Efmody® development in May 2021 to cover Efmody® and subsequently triggered the receiving the upfront payment.

Citrine, a therapeutics platform company focused on the Greater China market, has licensed the registration and commercialisation rights for the two products in China, Hong Kong, Taiwan and Macau and continues to plan for a New Drug Application (NDA) submission to the National Medical Products Administration in 2021 for Alkindi®.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014 (MAR).

Further information online


Digital Edition

LMUK 49.7 Nov 2024

November 2024

News - Research & Events News   - News & Views Articles - They’re burning the labs... Spotlight Features - Incubators, Freezers & Cooling Equipment - Pumps, Valves & Liquid Hand...

View all digital editions

Events

MEDICA 2024

Nov 11 2024 Dusseldorf, Germany

FILTECH

Nov 12 2024 Cologne, Germany

Intech

Nov 12 2024 Tel Aviv, Israel

analytica China

Nov 18 2024 Shanghai, China

Pharma Asia

Nov 20 2024 Karachi, Pakistan

View all events